The interplay of drug therapeutics and immune responses to SARS-CoV-2  

作　　者：Valeria Fumagalli Matteo Iannacone 

机构地区：[1]Division of Immunology,Transplantation,and Infectious Diseases,IRCCS San Raffaele Scientific Institute,Milan,Italy [2]Vita-Salute San Raffaele University,Milan,Italy [3]Experimental Imaging Centre,IRCCS San Raffaele Scientific Institute,Milan,Italy

出　　处：《Cellular & Molecular Immunology》2024年第2期197-200,共4页中国免疫学杂志（英文版）

基　　金：supported by the European Research Council(ERC)Consolidator Grant 725038;the ERC Proof of Concept Grants 957502 and 101138728;the Italian Association for Cancer Research(AIRC)Grants 19891 and 22737;the Italian Ministry for University and Research Grants PE00000007(INF-ACT)and PRIN(2022FMESXL);a Funded Research Agreement from Asher Biotherapeutics and VIR Biotechnology.

摘　　要：The SARS-CoV-2 pandemic has necessitated rapid therapeutic and preventative responses.While vaccines form the frontline of defense,antiviral treatments such as nirmatrelvir have emerged as vital adjunctive measures,particularly for those unable or unwilling to be vaccinated.This review delves into the potential influence of nirmatrelvir on enduring immunity.In parallel,the potential of drug repurposing is explored,with bisphosphonates being examined for their possible effects against COVID-19 due to their immunomodulatory properties.The importance of rigorous clinical trials and careful interpretation of preliminary data is emphasized.

关 键 词：SARS-CoV-2 Nirmatrelvir BISPHOSPHONATES Adaptive immunity Drug repurposing 

分 类 号：R392[医药卫生—免疫学]